Showing 1 - 10 of 91
This paper compares the innovation performance of established pharmaceutical firms and biotech companies, controlling for differences in the scale and scope of research. We develop a structural model to analyze more than 3,000 drug R&D projects advanced to pre-clinical and clinical trials in the...
Persistent link: https://www.econbiz.de/10008501715
This paper measures differences in the innovation performance of different types of firms in the pharmaceutical industry. We compare the innovation performance of incumbent firms with entrants, controlling for differences in the scale and scope of research, both at the firm level and at the...
Persistent link: https://www.econbiz.de/10005061689
The advancement of technology in the biopharmaceutical industry has spearheaded the speed and scale of digitalization in various aspects. New drug development is becoming more complex, costly, and challenging. This paper examines how the pharmaceutical value chain model could integrate with the...
Persistent link: https://www.econbiz.de/10013171458
Innovation comprises the processes of invention and commercialization. While the importance of innovation, especially commercialization, has been widely recognized, existing studies have largely overlooked the commercialization process. By examining the determinants of uses and nonuses of...
Persistent link: https://www.econbiz.de/10009476150
Innovation comprises the processes of invention and commercialization. While the importance of innovation, especially commercialization, has been widely recognized, existing studies have largely overlooked the commercialization process. By examining the determinants of uses and nonuses of...
Persistent link: https://www.econbiz.de/10009463384
Persistent link: https://www.econbiz.de/10010248422
Persistent link: https://www.econbiz.de/10011498662
Innovation is commercialization of technology. Imperfections in markets for technology should leave marks on physical investments for innovation. Two types of transaction costs could affect innovative investments: royality stacking and hold-up threats. Backward references in firm's patent...
Persistent link: https://www.econbiz.de/10010308275
Persistent link: https://www.econbiz.de/10013162692
Persistent link: https://www.econbiz.de/10012604756